Mirae Asset Global Investments Co. Ltd. Grows Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 0.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 51,136 shares of the company’s stock after purchasing an additional 296 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Vaxcyte were worth $3,211,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its position in Vaxcyte by 3.8% during the third quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock worth $234,442,000 after buying an additional 167,501 shares during the period. Jennison Associates LLC lifted its position in Vaxcyte by 20.6% during the third quarter. Jennison Associates LLC now owns 1,754,691 shares of the company’s stock worth $89,454,000 after buying an additional 300,189 shares during the period. UBS Group AG lifted its position in Vaxcyte by 62.2% during the third quarter. UBS Group AG now owns 74,305 shares of the company’s stock worth $3,788,000 after buying an additional 28,483 shares during the period. Vanguard Group Inc. lifted its position in Vaxcyte by 0.6% during the third quarter. Vanguard Group Inc. now owns 8,284,246 shares of the company’s stock worth $422,331,000 after buying an additional 47,872 shares during the period. Finally, Barclays PLC lifted its position in Vaxcyte by 67.9% during the third quarter. Barclays PLC now owns 170,412 shares of the company’s stock worth $8,688,000 after buying an additional 68,904 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Grant Pickering sold 15,000 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $66.93, for a total value of $1,003,950.00. Following the completion of the sale, the chief executive officer now owns 477,847 shares in the company, valued at $31,982,299.71. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Grant Pickering sold 15,000 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $66.93, for a total value of $1,003,950.00. Following the completion of the sale, the chief executive officer now owns 477,847 shares in the company, valued at $31,982,299.71. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Mikhail Eydelman sold 1,667 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $73.87, for a total value of $123,141.29. Following the sale, the senior vice president now owns 20,710 shares of the company’s stock, valued at approximately $1,529,847.70. The disclosure for this sale can be found here. Over the last quarter, insiders sold 101,577 shares of company stock worth $6,940,475. 3.60% of the stock is currently owned by corporate insiders.

Vaxcyte Stock Performance

PCVX stock opened at $62.43 on Thursday. Vaxcyte, Inc. has a 1 year low of $40.74 and a 1 year high of $82.04. The firm has a market cap of $6.77 billion, a P/E ratio of -15.12 and a beta of 0.89. The stock has a 50-day simple moving average of $69.94 and a 200-day simple moving average of $60.85.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same quarter last year, the business posted ($0.73) earnings per share. On average, equities research analysts predict that Vaxcyte, Inc. will post -4.18 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PCVX shares. Bank of America raised their price objective on Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Needham & Company LLC restated a “buy” rating and issued a $95.00 price objective on shares of Vaxcyte in a report on Wednesday, April 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte has an average rating of “Buy” and an average price target of $78.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.